Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

*The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx (suzetrigine), for adults with moderate to severe acute pain. Developed by ...

Health and Human Services Secretary Robert F. Kennedy Jr. testified in front of the House Committee on Energy and Commerce ...

Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pain relief with fewer side effects, positioning it as a potential new standard of care.

The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

FDA approves new painkiller that shows promise and challenges ... The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows ...

This target has clinical and regulatory validation from the recent FDA approval of Vertex Pharmaceuticals’ pain drug, Journavx. By Frank Vinluan on May 27, 2025 4:09 pm. Share.

UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to ...

UT Health San Antonio Multispecialty and Research Hospital is the first hospital in Texas to approve a non-narcotic ...

So JOURNAVX is a NaV1.8 inhibitor, it is a medicine that targets this particular channel that has been called the holy grail of pain drug development, NAV 1.7 and NaV 1.8. We have programs in both ...